The combined application of TGF-β signaling pathway blockade and PD-1/PD-L1 blockade had the significant advantage in tumor control with conversion of tumor environment from excluded infiltrate subtype to immune inflamed subtype [49–51]. The gene discussed is PDCD1; the disease is neoplasm.